"""Quick demo showing 3-agent pipeline results (using cached/mock outputs)."""
import sys
import os
sys.path.insert(0, os.path.dirname(__file__))

def print_header(title):
    """Print formatted section header."""
    print("\n" + "=" * 70)
    print(f"  {title}")
    print("=" * 70)

def main():
    """Display what the 3-agent system produces."""
    
    print_header("üè• CLINICAL GUIDELINE RESEARCH ASSISTANT - DEMO")
    print("\n‚úÖ 3-Agent System: Query+Filter ‚Üí Retriever+Summarizer ‚Üí Fact-Check+Writer")
    print("üìã Example Query: 'diabetes management in elderly patients'")
    print("üí∞ Cost: $0.00 (FREE with Ollama!)\n")
    
    # ==================================================================
    # AGENT 1 OUTPUT
    # ==================================================================
    print("\n‚ñ∂ AGENT 1: Query+Filter Agent")
    print("-" * 70)
    print("Task: Expand query into optimized searches with MeSH terms\n")
    
    print("üìä Expanded Queries:")
    print("   1. (diabetes mellitus AND elderly) AND (management OR treatment)")
    print("   2. elderly population AND diabetes complications")
    print("   3. geriatric care AND glycemic control")
    
    print("\nüè∑Ô∏è  MeSH Terms Generated:")
    print("   ‚Ä¢ Diabetes Mellitus [MeSH]")
    print("   ‚Ä¢ Aged [MeSH]")
    print("   ‚Ä¢ Geriatrics [MeSH]")
    print("   ‚Ä¢ Blood Glucose Management [MeSH]")
    
    print("\n‚úì Domain Vetting: HIPAA compliant, FDA policy checked")
    
    # ==================================================================
    # AGENT 2 OUTPUT
    # ==================================================================
    print("\n‚ñ∂ AGENT 2: Retriever+Summarizer Agent")
    print("-" * 70)
    print("Task: Hybrid BM25+Vector search, then hierarchical summarization\n")
    
    print("üîç Retrieved 3 Clinical Documents:")
    print("   1. Diabetes Management in Elderly: Updated Guidelines 2023")
    print("   2. SGLT2 Inhibitors: Benefits and Risks in Geriatric Populations")
    print("   3. Hypoglycemia Prevention Strategies in Elderly Diabetics")
    
    print("\nüìÑ Hierarchical Summary:")
    print("   Synthesis: Current evidence supports individualized HbA1c targets")
    print("   of 7.0-8.0% for elderly diabetic patients to minimize hypoglycemia")
    print("   risk. Metformin remains first-line therapy when renal function permits.")
    
    print("\n‚ö†Ô∏è  Contradictions Detected: 1")
    print("   ‚Ä¢ SGLT2 inhibitors show cardiovascular benefits but require careful")
    print("     monitoring for dehydration in patients >75 years")
    
    # ==================================================================
    # AGENT 3 OUTPUT
    # ==================================================================
    print("\n‚ñ∂ AGENT 3: Fact-Check+Writer Agent")
    print("-" * 70)
    print("Task: Verify claims, write brief with citations, generate traceability\n")
    
    print("üìã Executive Brief (287 words):")
    print("-" * 70)
    brief = """
Diabetes management in elderly patients requires careful individualization 
to balance glycemic control with safety [1]. Current guidelines recommend 
HbA1c targets between 7.0-8.0% for most patients aged 65 and older, 
recognizing the increased risk of severe hypoglycemia in this population [1][2].

Metformin remains the first-line pharmacological therapy when renal function 
is adequate (eGFR >30 mL/min/1.73m¬≤) [1]. For patients requiring additional 
glucose-lowering therapy, SGLT2 inhibitors offer cardiovascular benefits but 
require monitoring for dehydration and urinary tract infections, particularly 
in those over 75 years [2].

Key risk mitigation strategies include regular glucose monitoring, medication 
review every 6 months, and patient education on hypoglycemia recognition [3]. 
Relaxed glycemic targets have been shown to reduce severe hypoglycemia events 
by up to 40% without significantly increasing long-term complications [3].

CONTRAINDICATION WARNING: SGLT2 inhibitors should be used cautiously in elderly 
patients with recurrent UTIs or volume depletion risk [2].
    """
    print(brief.strip())
    print("-" * 70)
    
    print("\nüìö Sources: 3")
    print("   [1] Smith J, Johnson M. \"Diabetes Management in Elderly\" (2023)")
    print("       DOI: 10.1234/diabetes.2023, Citations: 145")
    print("   [2] Lee A, Chen B. \"SGLT2 Inhibitors in Geriatric Populations\" (2023)")
    print("       DOI: 10.5678/cardio.2023, Citations: 89")
    print("   [3] Garcia R, Martinez E. \"Hypoglycemia Prevention Strategies\" (2023)")
    print("       DOI: 10.9012/endo.2023, Citations: 67")
    
    print("\n‚ö†Ô∏è  Risk Flags: 2")
    print("   ‚Ä¢ [MEDIUM] Contraindication: SGLT2 use in volume-depleted elderly")
    print("   ‚Ä¢ [LOW] Study bias: Industry-funded SGLT2 trials")
    
    print("\nüîç Traceability Appendix (3 claims verified):")
    print("   Claim 1: \"HbA1c targets 7.0-8.0% for elderly\"")
    print("   ‚Üí Source [1], Confidence: 0.95, Status: VERIFIED")
    print("   ‚Üí Passage: \"Individualized HbA1c targets of 7.0-8.0% reduce...")
    
    print("   Claim 2: \"SGLT2 inhibitors show cardiovascular benefits\"")
    print("   ‚Üí Source [2], Confidence: 0.88, Status: VERIFIED")
    print("   ‚Üí Passage: \"SGLT2 inhibitors show cardiovascular benefits...")
    
    print("   Claim 3: \"Relaxed targets reduce hypoglycemia by 40%\"")
    print("   ‚Üí Source [3], Confidence: 0.92, Status: VERIFIED")
    print("   ‚Üí Passage: \"Evidence shows that relaxed glycemic targets...")
    
    # ==================================================================
    # SUMMARY
    # ==================================================================
    print_header("‚úÖ COMPLETE DELIVERABLE PACKAGE")
    
    print("\nüì¶ Generated Outputs:")
    print("   ‚úì Executive Brief (287 words) with inline citations [1][2][3]")
    print("   ‚úì Source List with DOIs, authors, quality scores")
    print("   ‚úì Risk Flags for contradictions and safety concerns")
    print("   ‚úì Traceability Appendix mapping every claim ‚Üí source passages")
    
    print("\nüéØ Quality Metrics:")
    print("   ‚Ä¢ Sources Retrieved: 3")
    print("   ‚Ä¢ Citations Confidence: >0.85")
    print("   ‚Ä¢ Claims Verified: 3/3 (100%)")
    print("   ‚Ä¢ Contradictions Detected: 1")
    print("   ‚Ä¢ Risk Flags: 2")
    
    print("\nüí∞ Total Cost: $0.00 (FREE with Ollama!)")
    print("‚è±Ô∏è  Processing Time: ~25-35 seconds (all 3 agents)")
    
    print_header("üöÄ SYSTEM CAPABILITIES DEMONSTRATED")
    
    print("\n‚ú® What This System Does:")
    print("   1. Expands clinical queries with MeSH terms (Agent 1)")
    print("   2. Searches BM25+Vector databases (Agent 2)")
    print("   3. Generates hierarchical summaries (Agent 2)")
    print("   4. Fact-checks every claim (Agent 3)")
    print("   5. Writes professional briefs with citations (Agent 3)")
    print("   6. Detects contradictions and safety risks (All agents)")
    print("   7. Provides full traceability claim‚Üísource (Agent 3)")
    
    print("\nüîß To Run Live:")
    print("   1. Ensure Ollama is running: ollama serve")
    print("   2. Run single agent: .\\py311.bat test_with_ollama.py")
    print("   3. Run full pipeline: .\\py311.bat demo_full_pipeline.py (slower)")
    
    print("\n" + "=" * 70 + "\n")


if __name__ == "__main__":
    main()
